Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bladder Urothelial Carcinoma, Metastatic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02437370
What this trial is testing

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Who this might be right for
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and Ureter+6 more
University of California, Davis 32
Testing effectiveness (Phase 2)Study completedNCT00310011
What this trial is testing

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Wake Forest University Health Sciences 71
Testing effectiveness (Phase 2)Ended earlyNCT00087295
What this trial is testing

S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 6
Post-approval studies (Phase 4)Looking for participantsNCT05962541
What this trial is testing

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Who this might be right for
Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza 327
Testing effectiveness (Phase 2)Study completedNCT02500121
What this trial is testing

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Who this might be right for
Urothelial CarcinomaBladder Cancer
Matthew Galsky 108
Testing effectiveness (Phase 2)Study completedNCT03159143
What this trial is testing

Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract

Who this might be right for
Metastatic Transitional Cell Cancer of the Urothelial Tract
Leonard Appleman 22
Testing effectiveness (Phase 2)Study completedNCT01191892
What this trial is testing

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUreter Cancer+1 more
Cardiff University 82
Early research (Phase 1)Study completedNCT02903914
What this trial is testing

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Who this might be right for
Metastatic CancerSolid TumorsColorectal Cancer (CRC)+7 more
Incyte Corporation 260
Large-scale testing (Phase 3)Active Not RecruitingNCT05092958
What this trial is testing

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Who this might be right for
Advanced Bladder Urothelial CarcinomaAdvanced Renal Pelvis Urothelial CarcinomaAdvanced Ureter Urothelial Carcinoma+15 more
National Cancer Institute (NCI) 654
Testing effectiveness (Phase 2)Study completedNCT00722553
What this trial is testing

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Who this might be right for
Carcinoma, Transitional CellBladder CancerBladder Neoplasm
Acrotech Biopharma Inc. 30
Post-approval studies (Phase 4)Looking for participantsNCT06764095
What this trial is testing

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis and Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+4 more
Mayo Clinic 75
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)Study completedNCT05077709
What this trial is testing

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Who this might be right for
Lung Cancer Non Small CellHead and Neck Squamous Cell CarcinomaUrothelial Carcinoma Bladder
IO Biotech 63
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Testing effectiveness (Phase 2)Study completedNCT00478361
What this trial is testing

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Who this might be right for
Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral Cancer+8 more
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT01282463
What this trial is testing

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Who this might be right for
Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more
Eli Lilly and Company 148
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 171
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Large-scale testing (Phase 3)Study completedNCT02426125
What this trial is testing

Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Eli Lilly and Company 530
Testing effectiveness (Phase 2)Ended earlyNCT03288545
What this trial is testing

Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic Neoplasms+4 more
Astellas Pharma Global Development, Inc. 348
Next Page